Every Form 4 that CONMED Corporation (CNMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CNMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNMD filings page.
CONMED Corp (CNMD) reported that director Kim Kelderman exercised 500 RSUs into 500 shares of Common Stock on September 8, 2026. The RSUs represented a contingent right to receive one share of common stock per unit under CONMED’s 2025 Long-Term Incentive Plan, which generally vests 100% after one year. No Rule 10b5-1 trading plan is indicated.
Gallagher John E reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp Executive Vice President & CFO John E. Gallagher received equity awards on July 15, 2026, including 30,536 stock options to purchase common shares at $42.79 per share and RSU grants of 26,875 and 35,054 shares under the Company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years (33%, 33%, 34% annually), while the stock options generally vest over four years in equal 25% installments, beginning one year after the grant date, and expire on July 15, 2036.
Martin Celine Christine reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp director Celine Christine Martin received a grant of restricted stock units as equity compensation. She was awarded 5,603 RSUs tied to CONMED common stock at a price of $0.00 per unit. Following this grant, her reported holdings of this RSU award total 5,603 units.
Each RSU represents a contingent right to receive one share of CONMED common stock under the company’s 2025 Long-Term Incentive Plan. The RSUs generally vest 100% after one year, meaning she will receive the underlying shares if vesting conditions are met and the award does not expire earlier.
Mirviss Jeffrey B. reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp director Jeffrey B. Mirviss reported a grant of 5,603 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of CONMED common stock and was awarded under the company’s 2025 Long-Term Incentive Plan. The RSUs generally vest 100% after one year, and Mirviss now holds 5,603 RSUs directly as reported in this filing. This is a compensation-related equity award rather than an open-market stock purchase or sale.
CONMED Corp director David M. Bronson reported compensation-related equity activity. On June 2, 2026, he exercised 668 restricted stock units into the same number of common shares, bringing his direct common stock holdings to 17,909 shares.
On June 1, 2026, he received a new award of 5,772 RSUs under CONMED’s 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to one share of common stock and generally vests 100% after one year. These transactions are reported as grants and derivative exercises rather than open-market buys or sells.
CONMED Corp director LaVerne H. Council reported compensation-related equity activity. On June 2, 2026, Council exercised 668 RSUs into the same number of common shares, bringing direct common stock holdings to 4,716 shares after the transaction. There were no open-market purchases or sales.
On June 1, 2026, Council received a grant of 5,772 RSUs under CONMED’s 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock and is generally scheduled to vest 100% after one year, aligning the director’s compensation with future company performance.
CONMED Corp director Kim Kelderman received a grant of 5,772 restricted stock units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one share of CONMED common stock under the company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest 100% after one year, aligning Kelderman’s compensation with shareholder interests over that period. Following this award, Kelderman holds 5,772 RSUs directly, which may convert into the same number of common shares if the vesting conditions are satisfied.
CONMED Corp director Charles Farkas reported routine equity compensation activity. On June 1, 2026, he received a grant of 5,772 RSUs, each representing a right to one share of common stock under the Company’s 2025 Long-Term Incentive Plan, generally vesting 100% after one year. On June 2, 2026, he exercised 668 RSUs into the same number of CONMED common shares at a stated price of $0.00 per share, bringing his direct common stock holdings to 15,527 shares. After the exercise, the specific 668-unit RSU award shows no remaining balance, while the newer 5,772-unit grant reflects his continuing derivative position.
CONMED Corp director Mark Kaye reported equity compensation activity, not open-market trading. He received an award of 5,772 restricted stock units (RSUs), each representing a contingent right to one share of CONMED common stock under the company’s 2025 Long-Term Incentive Plan, generally vesting 100% after one year.
On a separate line, 668 RSUs were converted into 668 shares of common stock at a stated price of $0.00 per share, reflecting the non-cash nature of this compensation. Following this exercise, Kaye directly holds 820 shares of common stock and retains 5,772 unvested RSUs scheduled to vest after their one-year period, subject to plan terms.
CONMED Corp director Barbara J. Schwarzentraub reported equity compensation and a routine option-like exercise. She received 5,772 RSUs on June 1, 2026, each representing a contingent right to one share of common stock under the 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after one year. On June 2, 2026, 668 RSUs were exercised and converted into 668 shares of common stock, leaving her with 5,012 shares of common stock held directly. A separate line shows 1,442 shares of common stock held indirectly by The Barbara J. Schwarzentraub Trust.
Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp President & CEO Pat Beyer received a grant of 28,145 RSUs, representing a $1 million target-value equity award. The RSUs are scheduled to vest over three years in three equal annual tranches starting April 1, 2026, with a two-year post-vest holding period on net after-tax shares. Following this grant, Beyer directly holds 28,145 RSUs tied to CONMED common stock, designed to align compensation with longer-term company performance.
Lalomia Brent reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation reported that Executive VP RA, QA Brent Lalomia received a corrected grant of 17,198 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan. Each RSU represents one share of common stock, vesting 33% after one year, 33% after two years, and 34% after three years.
The filing explains that this amended Form 4 updates the originally reported 9,554 RSUs to include a special award of 7,644 additional RSUs, bringing the total grant to 17,198 units.
Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation reported an amended Form 4 showing that executive Matthew Schabacker, VP GM Advanced Surgical, received a corrected grant of 17,471 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan.
Each RSU represents a contingent right to one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and 34% in the third year. The amendment clarifies that this total includes a special award of 7,644 RSUs in addition to the originally reported 9,827 RSUs.
Foust Hollie K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation granted General Counsel and Corporate Secretary Hollie K. Foust 18,563 restricted stock units (RSUs) under its 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs generally vest over three years, with 33% vesting after one year, another 33% in the second year, and 34% in the third year. This Form 4/A amends a prior report to correct the grant amount, noting that a special award of 7,644 RSUs was added to the originally reported 10,919 RSUs to reach the total of 18,563 RSUs.
Ferrell John D. reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation’s Executive Vice President – HR, John D. Ferrell, reported a compensation-related grant of 16,926 restricted stock units (RSUs). The RSUs were awarded under the company’s 2025 Long-Term Incentive Plan and generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years.
This amended Form 4 corrects the originally reported grant amount by reflecting an additional special award of 7,644 RSUs on top of the previously reported 9,282 RSUs, bringing the total to 16,926 RSUs tied to an equivalent number of common shares.
SHAGORY PETER K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation executive Peter K. Shagory received a corrected equity award totaling 16,926 restricted stock units (RSUs). Each RSU represents a right to receive one share of CONMED common stock under the Company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and 34% in the third year. This Form 4/A amends the prior report to reflect that a special award of 7,644 RSUs was granted in addition to the originally reported 9,282 RSUs, for the total 16,926 RSUs now shown as held directly following the transaction.
CONMED Corp executive Brent Lalomia exercised restricted stock units and received additional common shares as compensation. On March 6, 2026, 75 RSUs converted into 75 shares of common stock, and 26 of those shares were withheld at a price of $39.90 per share to cover tax obligations. After these transactions, Lalomia directly held 915.057 shares of CONMED common stock. A footnote also clarifies that prior reported holdings have been adjusted to exclude 140 shares that were previously reported in error.
Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that executive Matthew Schabacker, VP GM Advanced Surgical, received equity awards consisting of 9,827 restricted stock units and options to purchase 11,646 shares of common stock. The RSUs generally vest over three years, while the stock options generally vest in equal parts over four years.
Ferrell John D. reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp Executive Vice President of HR John D. Ferrell reported equity awards in the form of restricted stock units and stock options. He was granted 9,282 RSUs, each representing one share of common stock, which generally vest over three years in 33%, 33%, and 34% annual installments. He also received options to purchase 10,999 shares of common stock, generally vesting in equal 25% installments over four years under the 2025 Long-Term Incentive Plan.
Pelletier Johonna Marie reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that Treasurer and VP, Tax Johonna Marie Pelletier received a grant of 5,896 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of CONMED common stock under the 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and the remaining 34% in the third year, encouraging multi‑year retention and alignment with shareholders.
SHAGORY PETER K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp granted equity awards to executive Peter K. Shagory, EVP, Strategy & Corporate Development. He received 9,282 RSUs (Restricted Stock Units), each representing one future share of common stock, under the company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years from the March 2, 2026 grant date. He was also granted 10,999 stock options under the same plan, which generally vest in equal 25% installments over four years, starting one year after the grant date.
CONMED Corp executive Brent Lalomia reported equity awards that increase his stake-based compensation. On March 2, 2026, he acquired 9,554 RSUs, each representing one future share of common stock, and 11,322 stock options granted at no cost per option.
The RSUs generally vest over three years in 33%, 33%, and 34% annual installments, while the options generally vest in four equal annual installments. Both awards were granted under CONMED’s 2025 Long-Term Incentive Plan, tying a portion of his compensation to the company’s longer-term performance.
Foust Hollie K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that its General Counsel and Corporate Secretary, Hollie K. Foust, received equity awards in the form of restricted stock units and stock options. The grant included 10,919 RSUs, each representing a right to receive one share of CONMED common stock.
The RSUs were awarded under the company’s 2025 Long-Term Incentive Plan and generally vest over three years, with 33% vesting after the first and second years and 34% after the third year. Foust was also granted 12,940 options to purchase common stock under the same plan, which generally vest in equal 25% installments over four years starting one year after the grant date.
CONMED Corp reported that VP Corporate Controller Andrew James Moller acquired 5,896 restricted stock units (RSUs) as a grant of equity compensation. Each RSU represents a contingent right to receive one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting after one year, another 33% after two years, and the remaining 34% after three years, subject to the terms of the company’s 2025 Long-Term Incentive Plan.
Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp President & CEO Pat Beyer received new equity awards, increasing her direct holdings through compensation grants rather than open‑market trades. On March 2, 2026, she was granted 28,800 RSUs, each representing a right to one CONMED common share, and 68,258 stock options.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% the second year, and 34% the third year under CONMED’s 2025 Long-Term Incentive Plan. The stock options were also granted under the 2025 plan and generally vest in equal 25% installments over four years, beginning one year after the grant date.
CONMED Corp director Mark Kaye reported acquiring 152 shares of common stock through the exercise and conversion of 152 RSUs on February 24, 2026. Each RSU represents a right to receive one share of common stock under the company’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan.
The RSUs generally vest 100% after one year, with vesting accelerated immediately if the director’s service terminates. After this transaction, Kaye directly holds 152 shares of CONMED common stock.
CONMED Corp (CNMD) reported an insider stock transaction by its Chief Information Officer. On 11/21/2025, the officer sold 257 shares of CONMED common stock in an open market transaction at a price of $41.21 per share. Following this sale, the filing shows the officer beneficially owning 0 shares directly.
This is a routine Form 4 disclosure required by U.S. securities laws whenever company insiders buy or sell the company’s stock. It does not, by itself, explain the officer’s reasons for the transaction or signal any change in the company’s business operations.
CONMED Corporation’s Chief Information Officer, Richard Glaze, reported the settlement of restricted stock units in a Form 4 filing. On 11/20/2025, 375 RSUs were converted into shares of common stock at an exercise price of $0 per share, increasing his directly held common stock to 375 shares.
To cover taxes due on this vesting, 118 shares of common stock were disposed of at $40.63 per share, leaving 257 shares of common stock held directly after the withholding. Following the transaction, 750 RSUs remain outstanding, each representing a contingent right to receive one share of CONMED common stock.
CONMED Corp (CNMD): Insider transaction reported. The company’s Executive Vice President & CFO reported selling 3,500 shares of common stock at $43 on 11/06/2025. Following this open‑market sale, the reporting person beneficially owns 1,836 shares, held directly. The filing indicates the report was made by one reporting person.
CONMED (CNMD) disclosed an insider equity transaction. On 11/04/2025, the General Counsel & Corporate Secretary converted 4,000 RSUs into common stock (code M) at $0 and satisfied taxes by withholding 1,114 shares at $45.71 per share (code F). After these transactions, 2,886 common shares were owned directly. The RSUs are under the 2018 Long‑Term Incentive Plan and vest over two years, 50% after year 1 and 50% after year 2.
CONMED Corp (CNMD) insider transaction: Executive Vice President & CFO Todd W. Garner reported RSU-related activity on 10/31/2025. He acquired 7,500 shares of common stock at $0 upon settlement of restricted stock units (transaction code M), then had 2,164 shares withheld at $44 per share for taxes (code F).
After these transactions, he holds 5,336 shares directly. He also reports 15,227 RSUs as derivative securities beneficially owned following the transactions. Each RSU represents a right to receive one share of common stock. The RSUs are under the Company’s 2018 Long‑Term Incentive Plan, vesting over two years with 33% after year 1 and 67% after year 2.